Rituximab plus CDE for HIV-related Non-Hodgkins Lymphoma (NHL)
1 December 2003. Related: Conference reports, Antiretrovirals, Cancer and HIV.
Antiretrovirals
FTC (emtricitabine, Emtriva) approved in Europe
1 December 2003. Related: Antiretrovirals.
EMEA recommend approval for atazanavir for treatment experienced patients
1 December 2003. Related: Antiretrovirals.
Fosamprenavir (Lexiva) approved in US
1 December 2003. Related: Antiretrovirals.
US paediatric, adult and maternal-child guidelines updated
1 December 2003. Related: Antiretrovirals.
ddI may retain activity in nucleoside experienced patients
1 November 2003. Related: Conference reports, Antiretrovirals.
Studies and strategies with existing drugs
1 November 2003. Related: Conference reports, Antiretrovirals, Treatment strategies.
Incremental progress with new antiviral drugs
1 November 2003. Related: Conference reports, Antiretrovirals.
Atazanavir ‘named-patient’ access extended in the UK and includes 150mg capsule
1 November 2003. Related: Antiretrovirals.
Another triple nuke failure: abacavir/ddI/d4T
1 November 2003. Related: Antiretrovirals.
FDA announces changes to ritonavir package insert
1 November 2003. Related: Antiretrovirals.
New atazanavir information
1 October 2003. Related: Conference reports, Antiretrovirals.
Boosted PI therapy antiretrovirals in treatment-experienced patients: SQV/r, ATV, ATV/r
1 October 2003. Related: Conference reports, Antiretrovirals.
Tenofovir, resistance and K65R and concomitant nucleosides
1 September 2003. Related: Conference reports, Antiretrovirals, Drug resistance.
Mitochondrial toxicity with AZT and d4T – and benefits of switch to abacavir
1 September 2003. Related: Conference reports, Antiretrovirals, Lipodystrophy and metabolic complications.
Nevirapine and MTCT: the single-dose backlash
1 September 2003. Related: Conference reports, Antiretrovirals, Women's health, Pregnancy, Paediatric care.
Triple nucleoside combinations fail patients again
1 September 2003. Related: Conference reports, Antiretrovirals.
Nucleoside-sparing regimens
1 September 2003. Related: Conference reports, Antiretrovirals, Treatment strategies.
Dual boosted PIs in salvage therapy
1 September 2003. Related: Conference reports, Antiretrovirals.
BMS reports on atazanavir efficacy and safety in treatment experienced patients
1 September 2003. Related: Conference reports, Antiretrovirals.
Unsupervised treatment interruptions are associated with increased risk of AIDS or death
1 September 2003. Related: Conference reports, Antiretrovirals.
Step-wise intervention eases diarrhoea linked to PI nelfinavir (Viracept) therapy
1 September 2003. Related: Conference reports, Antiretrovirals, Side effects.
Lessons learned from early HAART in acute HIV infection
1 September 2003. Related: Conference reports, Antiretrovirals, Treatment strategies.
CD4 cell reconstitution is significantly slower in older patients
1 September 2003. Related: Conference reports, Antiretrovirals, Basic science and immunology.
Pharmacology studies at the 2nd IAS conference
1 September 2003. Related: Conference reports, Antiretrovirals, Pregnancy, PK and drug interactions.
T-20 launched in UK
1 September 2003. Related: Antiretrovirals.
US approval of FTC (emtricitabine)
1 September 2003. Related: Antiretrovirals.
T-20 approved in Europe
1 July 2003. Related: Antiretrovirals.
Tenofovir European licence extended to include first-line therapy
1 July 2003. Related: Antiretrovirals.
FDA approves atazanavir in US – a once daily protease inhibitor
1 July 2003. Related: Antiretrovirals.
Atanazavir and saquinavir in salvage therapy: reduced effect on lipids shown in pilot study
1 July 2003. Related: Antiretrovirals.
Major change to OPTIMA salvage therapy study in the UK
1 July 2003. Related: Antiretrovirals.
New 625mg formulations of nelfinavir
1 June 2003. Related: Antiretrovirals.
Lopinavir suitable for TDM
1 June 2003. Related: Antiretrovirals.
Less diarrhoea and bioequivalence with the new nelfinavir 625mg tablet
1 May 2003. Related: Conference reports, Antiretrovirals, PK and drug interactions, Side effects.
T-20 access programme to continue in UK for a further two months
1 May 2003. Related: Antiretrovirals.
Durability and success capability of HAART: 4.5 years follow-up
1 May 2003. Related: Antiretrovirals.
Older HIV-positive patients in the era of HAART: changing of a scenario
1 May 2003. Related: Antiretrovirals.
Immune reconstitution in older HIV-positive individuals
1 May 2003. Related: Antiretrovirals, Treatment strategies.
Pipeline compounds in Phase 2/3 Studies
1 April 2003. Related: Conference reports, Antiretrovirals.
96-week results show tenofovir-including regimen has side-effect advantages over d4T regimen in treatment naïve patients
1 April 2003. Related: Conference reports, Antiretrovirals.
2NN results – nevirapine and efavirenz in prospective randomised head-to-head study
1 April 2003. Related: Conference reports, Antiretrovirals.
NIH/NIAID study of generic drugs shows results consistent with stringent manufacturing standards
1 April 2003. Related: Conference reports, Antiretrovirals, Treatment access, PK and drug interactions.
Treatment interruptions: cycles, pauses, are just plain stopping?
1 April 2003. Related: Conference reports, Antiretrovirals, Treatment strategies.
Trizivir-only arm closed in PI-sparing, naïve therapy trial
1 April 2003. Related: Antiretrovirals, Other news.
Fosamprenavir expanded access in UK
1 April 2003. Related: Antiretrovirals, Other news.
Roche prices enfuvirtide (T-20) at €18,980 a year – making it the most expensive HIV drug yet
1 April 2003. Related: Antiretrovirals.
European positive opinion for tenofovir for first-line therapy
1 April 2003. Related: Antiretrovirals.
Efficacy and safety of a quadruple combination Combivir + abacavir + efavirenz regimen in antiretroviral treatment-naive HIV-1-infected adults: La Francilienne
1 March 2003. Related: Antiretrovirals.
Combination of three generic drugs in one pill meets bioequivalence criteria when compared with the branded drugs: Triomune vs d4T/3TC/NVP
1 February 2003. Related: Conference reports, Antiretrovirals, Treatment access.
An overview of the conference
1 February 2003. Related: Conference reports, Antiretrovirals, Lipodystrophy and metabolic complications.
Pharmacokinetic evaluation of tenofovir and enteric-coated ddI
1 February 2003. Related: Conference reports, Antiretrovirals, PK and drug interactions.
The advantages of fosamprenavir; comparing saquinavir/r to lopinavir/r; reducing viral load to <3 copies; AZT-d4T cross resistance; and rising HCV rates
1 February 2003. Related: Conference reports, Antiretrovirals, Treatment strategies, Hepatitis coinfection, Drug resistance.
Enfuvirtide (T-20): predicting success and modelling survival benefits
1 February 2003. Related: Conference reports, Antiretrovirals, Drug resistance.
Virologic failure among treatment-naive patients taking tenofovir DF or stavudine in combination with lamivudine and efavirenz
1 February 2003. Related: Conference reports, Antiretrovirals.
Comparison of the efficacy and safety of tenofovir vs. d4T when used in combination with 3TC and efavirenz in ARV-naive patients
1 February 2003. Related: Conference reports, Antiretrovirals, Side effects, Lipodystrophy and metabolic complications.
Safety profile of tenofovir in treatment-experienced patients
1 February 2003. Related: Conference reports, Antiretrovirals, Side effects.
Roche and Trimeris able to make enough enfuvirtide (T-20) for only 12,000 people this year, 32,000 next year, citing difficulties in the manufacturing process
1 February 2003. Related: Antiretrovirals.
Vertex Pharmaceuticals announces submission of NDA/MAA filings in US and Europe for amprenavir pro-drug (GW433908)
1 February 2003. Related: Antiretrovirals.
BMS submits new drug application for investigational protease inhibitior atazanavir
1 February 2003. Related: Antiretrovirals.
Europe and America approve once-a-day stavudine (d4T, Zerit)
1 February 2003. Related: Antiretrovirals.
Tenofovir as HIV prevention: study to reduce HIV transmission in sexually active adults
1 February 2003. Related: Antiretrovirals.
Boehringer chooses dose for phase III studies of tipranavir/ritonavir PI combination
1 February 2003. Related: Antiretrovirals.
Boosted PIs: differences emerging in efficacy, tolerability, lipids
1 December 2002. Related: Antiretrovirals.
Europe steps in to protect discounted drugs for developing countries
1 December 2002. Related: Antiretrovirals.